Bulk Inquiry
BIBW 2992
- Afatinib
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C24H25ClFN5O3
- MW: 485.94
Description
Second generation tyrosine kinase inhibitor (TKI) that irreversibly inhibits human epidermal receptor 2 (Her2 or ErbB 2) and EGFR (HER1) kinases. An investigational drug for breast cancer as well as other EGFR and Her2 driven cancers such as NSCLC and Head-and-Neck
More Information
| Parent CAS No. | 850140-72-6 |
|---|---|
| Chemical Name | (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide |
| MFCD | MFCD12407405 |
| Short Description | EGFR/HER2 inhibitor |
References
- N Minkovsky and A Berezov. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr. Opin. Investig. Drugs 2008, 9(12), 1336–46.
- D Li et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27, 4702–4711.
- C Campas et al. BIBW-2992. Dual EGFR/HER2 inhibitor, oncolytic. Drugs Fut. 2008, 33(8), 649.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1128 | Erlotinib hydrochloride |
From $77.00 |
| 1393 | Gefitinib |
From $77.00 |
| 1395 | Lapatinib ditosylate |
From $88.00 |
| 1398 | Sunitinib malate |
From $88.00 |
| 1411 | Vandetanib |
From $55.00 |
| 1414 | AG 013736 |
From $55.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1433 | CI 1033 |
From $66.00 |
| 1461 | Cediranib |
From $77.00 |
| 1506 | WZ 4002 |
From $77.00 |
| 1526 | Neratinib |
From $88.00 |
| 1537 | CP 724714 |
From $88.00 |
| 1547 | OSI 930 |
From $99.00 |
| 1632 | OSI 420 |
From $99.00 |
| 1637 | Vatalanib |
From $82.50 |
| 1638 | ABT 869 |
From $88.00 |
| 1653 | AEE 788 |
From $88.00 |
| 1662 | CP 547632 |
From $77.00 |
| 1665 | Pelitinib |
From $99.00 |
| 1667 | SU 5402 |
From $66.00 |
| 1678 | Regorafenib |
From $77.00 |
| 1717 | Tivozanib |
From $88.00 |
| 1760 | EGFR Inhibitor [879127-07-8] |
From $132.00 |
| 1768 | AMG 706 |
From $115.50 |
